LabCompass

John Byrd

Medicine · The Ohio State University

OpenAlex
Established · publishing since 1976Rising activity
Chronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia ResearchMonoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and TreatmentEpigenetics and DNA Methylation

Publications

23

Citations

310

Est. group size

—

Recurring co-author estimate

Active years

50

Publishing since 1976

Research summary
AI-generated

John Byrd's research focuses on blood cancers, particularly chronic lymphocytic leukemia and acute myeloid leukemia, including the development of antibody-based and targeted drug therapies. Recent work includes a clinical trial testing a menin inhibitor drug (revumenib) for a genetically defined subtype of relapsed or refractory acute leukemia. This research area involves clinical trials and translational studies aimed at improving treatments for patients with these blood cancers.

Leukemia and lymphoma treatmentTargeted cancer therapiesClinical trials in hematologic malignanciesMonoclonal antibody therapiesCancer epigenetics

Publication output has been low and irregular over the last decade, with several years showing no recorded publications followed by a modest increase in 2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 1.2/year recently
1718192020: 1 publication202021: 3 publications21222023: 1 publication232024: 1 publication242025: 4 publications42526
Recent publications
Publishes in
  • The Journal of Immunology×2
  • Clinical Lymphoma Myeloma & Leukemia×2
  • Journal of Clinical Oncology×1
  • Journal of Clinical Medicine×1
  • Experimental Hematology and Oncology×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile